• Explore /
  • Poster
  • / A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.

A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Johanna C. Bendell , Ivor John Percent , Robert Waide Weaver , Cynthia Coo Chua , Henry Q. Xiong , Allen Lee Cohn , Ahmed Zakari , Jaswinder Singh , Mark Kozloff , Caressa Lietman , Cassie Michelle Lane , Suzanne Fields Jones , Lindsey H. Finney , Sean Carmody , Mark Sanders Womack

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02317991

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 365)

Abstract #

365

Poster Bd #

D20

Abstract Disclosures

Similar Posters

First Author: Dandan Yu

First Author: Anica Högner

Poster

2020 Gastrointestinal Cancers Symposium

Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC).

Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC).

First Author: Daisaku Kamiimabeppu

First Author: Justin Moser